title: Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study.
abstract: BACKGROUND
  Insulin resistance (IR) is part of the metabolic syndrome (Mets) that develops after lifestyle changes and obesity. Although the association between Mets and myocardial injury is well known, the effect of IR on myocardial damage remains unclear.
  
  
  RESULTS
  We studied 2200 normal subjects who participated in a community-based health check in the town of Takahata in northern Japan. The presence of IR was assessed by homeostasis model assessment ratio, and the serum level of heart-type fatty acid binding protein (H-FABP) was measured as a maker of silent and ongoing myocardial damage. H-FABP levels were significantly higher in subjects with IR and Mets than in those without metabolic disorder regardless of gender. Multivariate logistic analysis showed that the presence of IR was independently associated with latent myocardial damage (odds ratio: 1.574, 95% confidence interval 1.1-2.3) similar to the presence of Mets.
  
  
  CONCLUSIONS
  In a screening of healthy subjects, IR and Mets were similarly related to higher H-FABP levels, suggesting that there may be an asymptomatic population in the early stages of metabolic disorder that is exposed to myocardial damage and might be susceptible to silent heart failure.
authors.affiliation: Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
authors.forename: Taro
authors.initials: T
authors.lastname: Narumi
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Shishido
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kiribayashi
authors.forename: Shinpei
authors.initials: S
authors.lastname: Kadowaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nishiyama
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Takanori
authors.initials: T
authors.lastname: Arimoto
authors.forename: Takehiko
authors.initials: T
authors.lastname: Miyashita
authors.forename: Takuya
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Tetsu
authors.initials: T
authors.lastname: Watanabe
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shibata
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Konta
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ueno
authors.forename: Takeo
authors.initials: T
authors.lastname: Kato
authors.forename: Takamasa
authors.initials: T
authors.lastname: Kayama
authors.forename: Isao
authors.initials: I
authors.lastname: Kubota
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D009202:Cardiomyopathies / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism*; D003430:Cross-Sectional Studies; D042241:Early Diagnosis; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000209:etiology; D015994:Incidence; D007333:Insulin Resistance; D007564:Japan / Q000453:epidemiology; D008297:Male; D008403:Mass Screening; D024821:Metabolic Syndrome / Q000503:physiopathology*; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D012727:Sex Characteristics
chemical_list: D015415:Biomarkers; C493408:FABP3 protein, human; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins; D020097:Natriuretic Peptide, Brain